Boston, MA -- (SBWIRE) -- 09/04/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (OmniVision Technologies, Inc. (NASDAQ:OVTI), Novavax, Inc. (NASDAQ:NVAX), Halozyme Therapeutics, Inc. (NASDAQ:HALO), Nuverra Environmental Solutions Inc (NYSE:NES)
OmniVision Technologies, Inc. (NASDAQ:OVTI) shares decreased 0.61% to $15.35. The company on August 29 reported financial results for the first quarter of fiscal 2014 that ended on July 31, 2013. Revenues for the first quarter of fiscal 2014 were $373.7 million, as compared to $336.2 million in the fourth quarter of fiscal 2013, and $258.1 million in the first quarter of fiscal 2013. GAAP net income in the first quarter of fiscal 2014 was $23.1 million, or $0.42 per diluted share, as compared to net income of $8.9 million, or $0.17 per diluted share in the fourth quarter of fiscal 2013, and $2.3 million, or $0.04 per diluted share in the first quarter of fiscal 2013. Non-GAAP net income in the first quarter of fiscal 2014 was $31.7 million, or $0.55 per diluted share. Non-GAAP net income in the fourth quarter of fiscal 2013 was $17.5 million, or $0.31 per diluted share.
How Should Investors Trade OVTI After The Recent Volatility? Get Free Report Here
Novavax, Inc. (NASDAQ:NVAX) shares gained 1.59% to $3.20. The company on August 22 announced the number of shares tendered to it during the extended acceptance period for its recommended public offer to acquire all issued and outstanding shares and warrants (warrants series 2005-I and 2005-II) of Isconova AB ("Isconova"), which was first communicated on June 4, 2013, (the "Offer"), and which was extended to August 20, 2013.
How Should Investors Trade NVAX After The Recent Volatility? Get Free Report Here
Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares climbed 2.89% to $8.55. The company, on Sept. 2, announced that the European Commission has granted Roche European Union (EU) marketing authorization for the use of a time-saving subcutaneous (SC) formulation of Herceptin(R) (trastuzumab) for the treatment of HER2-positive breast cancer. This formulation utilizes Halozyme's recombinant human hyaluronidase (rHuPH20) and is administered in two to five minutes, rather than 30 to 90 minutes with the standard intravenous form.
Is HALO A Good Buy After The Recent Price Movement? Find Out Here
Nuverra Environmental Solutions Inc (NYSE:NES) stock increased 5.22% to $2.42. Saxena White P.A. on Sept. 3 has filed a securities fraud class action lawsuit in the United States District Court for the District of Arizona against Nuverra Environmental Solutions, Inc. ("Nuverra" or the "Company") (NYSE: NES) on behalf of investors who purchased or otherwise acquired the common stock of the Company during the period from August 6, 2012 through August 23, 2013 (the "Class Period").
Additionally, the company on August 8 announced financial results for the second quarter ended June 30, 2013. Revenues for the second quarter of 2013 were $165.5 million.Net loss was $(12.8) million in the second quarter of 2013. Looking forward, the Company expects second half 2013 revenues to be between $350 and $400 million, second half 2013 adjusted EBITDA to be between $75 and $85 million and second half 2013 capital expenditures of $25 to $30 million.
Is NES A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)